181 related articles for article (PubMed ID: 35963895)
41. GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma.
Zirngibl F; Ivasko SM; Grunewald L; Klaus A; Schwiebert S; Ruf P; Lindhofer H; Astrahantseff K; Andersch L; Schulte JH; Lode HN; Eggert A; Anders K; Hundsdoerfer P; Künkele A
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34285106
[TBL] [Abstract][Full Text] [Related]
42. Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.
Link BK; Kostelny SA; Cole MS; Fusselman WP; Tso JY; Weiner GJ
Int J Cancer; 1998 Jul; 77(2):251-6. PubMed ID: 9650561
[TBL] [Abstract][Full Text] [Related]
43. Release of cytokines and soluble cell surface molecules by PBMC after activation with the bispecific antibody CD3 x CD19.
Klein SC; Boer LH; de Weger RA; de Gast GC; Bast EJ
Scand J Immunol; 1997 Nov; 46(5):452-8. PubMed ID: 9393627
[TBL] [Abstract][Full Text] [Related]
44. Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.
Seckinger A; Delgado JA; Moser S; Moreno L; Neuber B; Grab A; Lipp S; Merino J; Prosper F; Emde M; Delon C; Latzko M; Gianotti R; Lüoend R; Murr R; Hosse RJ; Harnisch LJ; Bacac M; Fauti T; Klein C; Zabaleta A; Hillengass J; Cavalcanti-Adam EA; Ho AD; Hundemer M; San Miguel JF; Strein K; Umaña P; Hose D; Paiva B; Vu MD
Cancer Cell; 2017 Mar; 31(3):396-410. PubMed ID: 28262554
[TBL] [Abstract][Full Text] [Related]
45. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells.
Yu S; Zhang J; Yan Y; Yao X; Fang L; Xiong H; Liu Y; Chu Q; Zhou P; Wu K
J Exp Clin Cancer Res; 2019 Aug; 38(1):355. PubMed ID: 31412896
[TBL] [Abstract][Full Text] [Related]
46. Bispecific Antibody PD-L1 x CD3 Boosts the Anti-Tumor Potency of the Expanded Vγ2Vδ2 T Cells.
Yang R; Shen S; Gong C; Wang X; Luo F; Luo F; Lei Y; Wang Z; Xu S; Ni Q; Xue Y; Fu Z; Zeng L; Fang L; Yan Y; Zhang J; Gan L; Yi J; Zhou P
Front Immunol; 2021; 12():654080. PubMed ID: 34040604
[TBL] [Abstract][Full Text] [Related]
47. Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers.
Seckinger A; Majocchi S; Moine V; Nouveau L; Ngoc H; Daubeuf B; Ravn U; Pleche N; Calloud S; Broyer L; Cons L; Lesnier A; Chatel L; Papaioannou A; Salgado-Pires S; Krämer S; Gockel I; Lordick F; Masternak K; Poitevin Y; Magistrelli G; Malinge P; Shang L; Kallendrusch S; Strein K; Hose D
J Hematol Oncol; 2023 Dec; 16(1):117. PubMed ID: 38087365
[TBL] [Abstract][Full Text] [Related]
48. A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice.
Fisher TS; Hooper AT; Lucas J; Clark TH; Rohner AK; Peano B; Elliott MW; Tsaparikos K; Wang H; Golas J; Gavriil M; Haddish-Berhane N; Tchistiakova L; Gerber HP; Root AR; May C
Cancer Immunol Immunother; 2018 Feb; 67(2):247-259. PubMed ID: 29067496
[TBL] [Abstract][Full Text] [Related]
49. A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell-Mediated Immune Response against EGFR-Expressing Tumors.
King LA; Toffoli EC; Veth M; Iglesias-Guimarais V; Slot MC; Amsen D; van de Ven R; Derks S; Fransen MF; Tuynman JB; Riedl T; Roovers RC; Adang AEP; Ruben JM; Parren PWHI; de Gruijl TD; van der Vliet HJ
Cancer Immunol Res; 2023 Sep; 11(9):1237-1252. PubMed ID: 37368791
[TBL] [Abstract][Full Text] [Related]
50. CD47/SIRPα blocking enhances CD19/CD3-bispecific T cell engager antibody-mediated lysis of B cell malignancies.
Xu L; Wang S; Li J; Li B
Biochem Biophys Res Commun; 2019 Feb; 509(3):739-745. PubMed ID: 30611570
[TBL] [Abstract][Full Text] [Related]
51. Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate.
Waaijer SJ; Giesen D; Ishiguro T; Sano Y; Sugaya N; Schröder CP; de Vries EG; Lub-de Hooge MN
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217763
[TBL] [Abstract][Full Text] [Related]
52. A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces Antitumor Responses in Small Cell Lung Cancer.
Hipp S; Voynov V; Drobits-Handl B; Giragossian C; Trapani F; Nixon AE; Scheer JM; Adam PJ
Clin Cancer Res; 2020 Oct; 26(19):5258-5268. PubMed ID: 32554516
[TBL] [Abstract][Full Text] [Related]
53. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
54. Development of an antibody-like T-cell engager based on VH-VL heterodimer formation and its application in cancer therapy.
Jang S; Song J; Kim N; Bak J; Jung K; Park YW; Park BC; Kim HM
Biomaterials; 2021 Apr; 271():120760. PubMed ID: 33774526
[TBL] [Abstract][Full Text] [Related]
55. A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.
Bacac M; Fauti T; Sam J; Colombetti S; Weinzierl T; Ouaret D; Bodmer W; Lehmann S; Hofer T; Hosse RJ; Moessner E; Ast O; Bruenker P; Grau-Richards S; Schaller T; Seidl A; Gerdes C; Perro M; Nicolini V; Steinhoff N; Dudal S; Neumann S; von Hirschheydt T; Jaeger C; Saro J; Karanikas V; Klein C; Umaña P
Clin Cancer Res; 2016 Jul; 22(13):3286-97. PubMed ID: 26861458
[TBL] [Abstract][Full Text] [Related]
56. Preclinical Assessment of a MUC12-Targeted BiTE (Bispecific T-cell Engager) Molecule.
Pham E; Friedrich M; Aeffner F; Lutteropp M; Mariano NF; Deegen P; Dahlhoff C; Vogel F; Bluemel C; Harrold JM; Brandl C; Grinberg N; Rattel B; Coxon A; Bailis JM
Mol Cancer Ther; 2021 Oct; 20(10):1977-1987. PubMed ID: 34376583
[TBL] [Abstract][Full Text] [Related]
57. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma.
Moore PA; Zhang W; Rainey GJ; Burke S; Li H; Huang L; Gorlatov S; Veri MC; Aggarwal S; Yang Y; Shah K; Jin L; Zhang S; He L; Zhang T; Ciccarone V; Koenig S; Bonvini E; Johnson S
Blood; 2011 Apr; 117(17):4542-51. PubMed ID: 21300981
[TBL] [Abstract][Full Text] [Related]
58. Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody.
Staflin K; Zuch de Zafra CL; Schutt LK; Clark V; Zhong F; Hristopoulos M; Clark R; Li J; Mathieu M; Chen X; Johnston J; Low J; Ybarra R; Slaga D; Yang J; Ovacik M; Dybdal NO; Totpal K; Junttila MR; Ellerman D; Lee G; Dennis MS; Prell R; Junttila TT
JCI Insight; 2020 Apr; 5(7):. PubMed ID: 32271166
[TBL] [Abstract][Full Text] [Related]
59. Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor D-1-methyl-tryptophan.
Zhang X; Yang Y; Zhang L; Lu Y; Zhang Q; Fan D; Zhang Y; Zhang Y; Ye Z; Xiong D
J Hematol Oncol; 2017 Feb; 10(1):56. PubMed ID: 28228105
[TBL] [Abstract][Full Text] [Related]
60. Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens.
Friedrich M; Raum T; Lutterbuese R; Voelkel M; Deegen P; Rau D; Kischel R; Hoffmann P; Brandl C; Schuhmacher J; Mueller P; Finnern R; Fuergut M; Zopf D; Slootstra JW; Baeuerle PA; Rattel B; Kufer P
Mol Cancer Ther; 2012 Dec; 11(12):2664-73. PubMed ID: 23041545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
